BibTex format
@article{Alexander:2023:10.1016/j.ebiom.2022.104430,
author = {Alexander, JL and Mullish, BH and Danckert, NP and Liu, Z and Olbei, ML and Saifuddin, A and Tokizadeh, M and Ibraheim, H and Miguens, Blanco J and Roberts, LA and Bewshea, CM and Nice, R and Lin, S and Prabhudev, H and Sands, C and Horneffer, van der Sluis V and Lewis, M and Sebastian, S and Lees, CW and Teare, JP and Hart, A and Goodhand, J and Kennedy, NA and Korcsmaros, T and Marchesi, JR and Ahmad, T and Powell, N},
doi = {10.1016/j.ebiom.2022.104430},
journal = {EBioMedicine},
title = {The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients},
url = {http://dx.doi.org/10.1016/j.ebiom.2022.104430},
volume = {88},
year = {2023}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Background:Patients with inflammatory bowel disease (IBD) treated with anti-TNF therapy exhibit attenuated humoral immune responses to vaccination against SARS-CoV-2. The gut microbiota and its functional metabolic output, which are perturbed in IBD, play an important role in shaping host immune responses. We explored whether the gut microbiota and metabolome could explain variation in anti-SARS-CoV-2 vaccination responses in immunosuppressed IBD patients.Methods:Faecal and serum samples were prospectively collected from infliximab-treated patients with IBD in the CLARITY-IBD study undergoing vaccination against SARS-CoV-2. Antibody responses were measured following two doses of either ChAdOx1 nCoV-19 or BNT162b2 vaccine. Patients were classified as having responses above or below the geometric mean of the wider CLARITY-IBD cohort. 16S rRNA gene amplicon sequencing, nuclear magnetic resonance (NMR) spectroscopy and bile acid profiling with ultra-high-performance liquid chromatography mass spectrometry (UHPLC-MS) were performed on faecal samples. Univariate, multivariable and correlation analyses were performed to determine gut microbial and metabolomic predictors of response to vaccination.Findings:Forty-three infliximab-treated patients with IBD were recruited (30 Crohn's disease, 12 ulcerative colitis, 1 IBD-unclassified; 26 with concomitant thiopurine therapy). Eight patients had evidence of prior SARS-CoV-2 infection. Seventeen patients (39.5%) had a serological response below the geometric mean. Gut microbiota diversity was lower in below average responders (p = 0.037). Bilophila abundance was associated with better serological response, while Streptococcus was associated with poorer response. The faecal metabolome was distinct between above and below average responders (OPLS-DA R2X 0.25, R2Y 0.26, Q2 0.15; CV-ANOVA p = 0.038). Trimethylamine, isobutyrate and omega-muricholic acid were associated with better response, while succinate, phenylalanine, taurolithoc
AU - Alexander,JL
AU - Mullish,BH
AU - Danckert,NP
AU - Liu,Z
AU - Olbei,ML
AU - Saifuddin,A
AU - Tokizadeh,M
AU - Ibraheim,H
AU - Miguens,Blanco J
AU - Roberts,LA
AU - Bewshea,CM
AU - Nice,R
AU - Lin,S
AU - Prabhudev,H
AU - Sands,C
AU - Horneffer,van der Sluis V
AU - Lewis,M
AU - Sebastian,S
AU - Lees,CW
AU - Teare,JP
AU - Hart,A
AU - Goodhand,J
AU - Kennedy,NA
AU - Korcsmaros,T
AU - Marchesi,JR
AU - Ahmad,T
AU - Powell,N
DO - 10.1016/j.ebiom.2022.104430
PY - 2023///
SN - 2352-3964
TI - The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients
T2 - EBioMedicine
UR - http://dx.doi.org/10.1016/j.ebiom.2022.104430
UR - http://hdl.handle.net/10044/1/101403
VL - 88
ER -